Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies
The recall of Cyclizine Lactate due to GMP deficiencies poses significant risks to supply chains and market availability in the antiemetic sector. This situation necessitates close monitoring of regulatory responses and competitor actions to safeguard market positioning.
Company
Orbit Pharma Limited
Asset
Orbit
Indication
Neurology / Antiemetic
Status
Under Review
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The recall of Cyclizine Lactate due to GMP deficiencies poses significant risks to supply chains and market availability in the antiemetic sector. This situation necessitates close monitoring of regulatory responses and competitor actions to safeguard market positioning.
Why it matters
The recall of Cyclizine Lactate due to GMP deficiencies poses significant risks to supply chains and market availability in the antiemetic sector. This situation necessitates close monitoring of regulatory responses and competitor actions to safeguard market positioning.
What changed
Safety Signal
Analysis
Orbit Pharma Limited is recalling a batch of Cyclizine Lactate 50 mg/ml Solution for injection due to GMP deficiencies.
The recall of Cyclizine Lactate due to GMP deficiencies poses significant risks to supply chains and market availability in the antiemetic sector. This situation necessitates close monitoring of regulatory responses and competitor actions to safeguard market positioning.
Monitor for updates on the recall process and any regulatory actions taken by health authorities.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.